Premium Nahrungsergänzungsmittel | artgerecht

Insulin Secretagogue Therapy – Mechanism and Use

Insulin secretagogue therapy is a pharmacological approach to treating type 2 diabetes that stimulates the pancreas to release more of its own insulin.

Regular tips about health Regular tips about health

Things worth knowing about "Insulin Secretagogue Therapy"

Insulin secretagogue therapy is a pharmacological approach to treating type 2 diabetes that stimulates the pancreas to release more of its own insulin.

What Is Insulin Secretagogue Therapy?

Insulin secretagogue therapy refers to the therapeutic use of medications that act as insulin secretagogues -- agents that stimulate the beta cells of the pancreas to produce and release more insulin. This approach is primarily used in the treatment of type 2 diabetes mellitus, particularly when lifestyle modifications and first-line therapy with metformin are insufficient to achieve adequate blood glucose control.

Mechanism of Action

Insulin secretagogues stimulate insulin release from pancreatic beta cells. Depending on the drug class, the mechanism differs:

Sulfonylureas (e.g., glibenclamide, glimepiride, glipizide): Block ATP-sensitive potassium channels in the beta cell membrane, triggering membrane depolarization and insulin release. Their effect is largely independent of current blood glucose levels.
Glinides (e.g., repaglinide, nateglinide): Act similarly to sulfonylureas but with a shorter duration and more meal-related action. They are taken just before meals and primarily reduce postprandial blood glucose.
GLP-1 receptor agonists (e.g., semaglutide, liraglutide): Mimic the endogenous gut hormone GLP-1 (glucagon-like peptide-1) and enhance insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia.
DPP-4 inhibitors (e.g., sitagliptin, saxagliptin): Inhibit the enzyme dipeptidyl peptidase-4, which degrades GLP-1, thereby prolonging its insulinotropic effects.

Indications

Insulin secretagogue therapy is indicated in:

Type 2 diabetes mellitus, especially when beta cell function is still sufficiently preserved
Inadequate glycemic control despite dietary measures, physical activity, and metformin therapy
Patients with elevated cardiovascular risk (preferably using GLP-1 receptor agonists)

Dosage and Administration

Dosing depends on the specific drug class, the individual HbA1c target, and comorbidities such as renal or hepatic impairment. Key points include:

Sulfonylureas are generally taken orally once or twice daily.
Glinides are taken immediately before main meals and omitted if a meal is skipped.
GLP-1 receptor agonists are administered subcutaneously (under the skin), with some formulations given weekly.
DPP-4 inhibitors are taken orally once daily and are well tolerated in patients with renal impairment when doses are appropriately adjusted.

Side Effects

The main side effects associated with insulin secretagogue therapy include:

Hypoglycemia (low blood sugar): Most common with sulfonylureas and glinides, as these stimulate insulin release independent of blood glucose levels.
Weight gain: Frequently observed with sulfonylureas and glinides due to the anabolic effects of insulin.
Nausea, vomiting, and diarrhea: Particularly with GLP-1 receptor agonists, especially at the start of therapy.
Nasopharyngitis and urinary tract infections: Occasionally reported with DPP-4 inhibitors.

Contraindications and Precautions

Not all insulin secretagogues are suitable for every patient. Important restrictions include:

Sulfonylureas are contraindicated in severe renal impairment, liver disease, and during pregnancy.
Older patients face an increased risk of hypoglycemia with sulfonylureas.
GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Role in the Stepwise Treatment of Type 2 Diabetes

Insulin secretagogue therapy is an integral part of the stepwise management of type 2 diabetes. According to current guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), the choice of secretagogue is individualized -- taking into account comorbidities, hypoglycemia risk, body weight, and patient preference. GLP-1 receptor agonists have gained increasing importance due to their demonstrated cardiovascular and renoprotective benefits.

References

Davies MJ et al. - Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the ADA and the EASD. Diabetes Care, 2022;45(11):2753-2786.
American Diabetes Association Professional Practice Committee - Standards of Medical Care in Diabetes 2024. Diabetes Care, 2024;47(Suppl 1):S1-S321.
Inzucchi SE et al. - Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care, 2015;38(1):140-149.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.